Sugi Predict

Sugi Predict / Compounds / SCHEMBL5344223

SCHEMBL5344223

SCHEMBL5344223

CCC[C@H]1CC[C@H](CCc2ccc(OC(F)(F)F)cc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.47
▸ SLC6A4 P31645 4/20 0.44
▸ SLC6A3 Q01959 4/20 0.44
▸ ALDH1A1 P00352 1/20 0.43
▸ DRD2 P14416 2/20 0.43
▸ DRD4 P21917 2/20 0.43
▸ DRD3 P35462 2/20 0.43
▸ GCGR P47871 1/20 0.42
▸ MAOB P27338 2/20 0.41
▸ MAOA P21397 1/20 0.40
▸ KDM1A O60341 1/20 0.40
▸ RCOR1 Q9UKL0 1/20 0.40
▸ LIPE Q05469 1/20 0.40
▸ CARM1 Q86X55 1/20 0.40
▸ PRMT6 Q96LA8 1/20 0.40
▸ DAO P14920 1/20 0.40
▸ FFAR4 Q5NUL3 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5344231 1.00 TSHR (0.47) TSHRSLC6A4SLC6A3ALDH1A1DRD2
SCHEMBL8447740 0.96 TSHR (0.43) TSHRSLC6A4SLC6A3ALDH1A1DRD2
SCHEMBL4803252 0.96 TSHR (0.43) TSHRSLC6A4SLC6A3ALDH1A1DRD2
SCHEMBL4803267 0.96 TSHR (0.43) TSHRSLC6A4SLC6A3ALDH1A1DRD2
SCHEMBL7731651 0.92 GCGR (0.41) TSHRSLC6A4SLC6A3ALDH1A1DRD2
SCHEMBL6455066 0.92 TSHR (0.41) TSHRSLC6A4SLC6A3ALDH1A1DRD2
SCHEMBL7731655 0.92 GCGR (0.41) TSHRSLC6A4SLC6A3ALDH1A1DRD2
SCHEMBL6455063 0.92 TSHR (0.41) TSHRSLC6A4SLC6A3ALDH1A1DRD2
SCHEMBL9062477 0.91 TSHR (0.44) TSHRSLC6A4SLC6A3ALDH1A1DRD2
SCHEMBL9062473 0.91 TSHR (0.44) TSHRSLC6A4SLC6A3ALDH1A1DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7186447-B2 Two plane parallel support plates with frame form cell, with integrated non-linear elements for switching individual picture elements on support plates, and nematic liquid crystal mixture is present in cell, having positive dielectric anisotropy and high resistivity MERCK PATENT GMBH (DE) 2007-03-06 — — US disclosed
US-20050196551-A1 Matrix liquid crystal display WEBER GEORG (DE) 2005-09-08 — — US disclosed
US-6939880-B2 Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 2005-09-06 — — US disclosed
US-6905740-B2 The invention relates to a matrix liquid crystal display containing integrated non-linear elements and a liquid crystal mixture which has a particularly high resistivity. MERCK PATENT GMBH (DE) 2005-06-14 — — US disclosed
US-20030207046-A1 Matrix liquid crystal display MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2003-11-06 — — US disclosed
US-6562419-B1 Matrix liquid crystal display MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2003-05-13 — — US disclosed
US-6555570-B2 Growth hormone secretagogous with improved bioavailability NOVO NORDISK A/S (DE) 2003-04-29 — — US disclosed
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 — — US disclosed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 — — US disclosed
US-6127391-A A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 2000-10-03 — — US disclosed
WO-1991013947-A2 LIQUID CRYSTALLINE MEDIUM MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 1991-09-19 — — WO disclosed
EP-0445274-A1 LIQUID CRYSTALLINE MEDIUM. MERCK PATENT GMBH (DE) 1991-09-11 — — EP disclosed
EP-0438547-A1 SUPER-TWIST LIQUID CRYSTAL DISPLAY. MERCK PATENT GMBH (DE) 1991-07-31 — — EP disclosed
WO-1991010716-A1 MATRIX LIQUID CRYSTAL DISPLAY MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 1991-07-25 — — WO disclosed
WO-1991002779-A1 LIQUID CRYSTALLINE MEDIUM MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 1991-03-07 — — WO disclosed
EP-0414048-A2 Matrix-liquid crystal display MERCK PATENT GmbH (DE) 1991-02-27 — — EP disclosed
WO-1991000898-A1 SUPER-TWIST LIQUID CRYSTAL DISPLAY MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 1991-01-24 — — WO disclosed
EP-0394419-A1 MATRIX LIQUID CRYSTAL DISPLAY. MERCK PATENT GMBH (DE) 1990-10-31 — — EP disclosed
WO-1990004623-A1 MATRIX LIQUID CRYSTAL DISPLAY MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 1990-05-03 — — WO disclosed
EP-0365962-A1 Matrix-type liquid-crystal display MERCK PATENT GmbH (DE) 1990-05-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055261-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, IGFBP1 TSHR 63/4885SLC6A4 1787/4885SLC6A3 1621/4885
US-20030040483-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, GRPR TSHR 65/4885SLC6A4 1766/4885SLC6A3 1486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.